UCB completes mutual recognition procedure for Equasym XL

By Elaine Rigoli

Tampa, Fla., May 24 - UCB said it has successfully completed the European mutual recognition procedure for Equasym XL for use in the treatment of the symptoms of attention-deficit/hyperactivity disorder with the United Kingdom acting as the Reference Member State for the mutual recognition procedure.

All concerned member-states endorsed the summary of product characteristics. The national marketing authorizations are expected to be issued over the coming months. Equasym XL was launched in the United Kingdom, the first European market, in 2005.

Equasym XL 10, 20 and 30 mg capsules is indicated as part of a comprehensive treatment program for ADHD in children over six years of age when remedial measures alone prove insufficient, according to a news release.

UCB is a global biopharmaceutical company with worldwide headquarters in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.